Combined modality therapy in esophageal cancer: The Memorial experience

2003 ◽  
Vol 21 (4) ◽  
pp. 228-232 ◽  
Author(s):  
Sibyl E. Anderson ◽  
Bruce D. Minsky ◽  
Manjit Bains ◽  
David P. Kelsen ◽  
David H. Ilson
Keyword(s):  
Esophageal Cancer ◽  
Combined Modality Therapy ◽  
Combined Modality

Combined modality therapy for esophageal cancer

1997 ◽  
Vol 7 (3) ◽  
pp. 15-23 ◽  
Author(s):  
Charles D. Blanke ◽  
Hak Choy ◽  
Steven D. Leach
Keyword(s):  
Esophageal Cancer ◽  
Combined Modality Therapy ◽  
Combined Modality

Assessment of Quality of Life in Patients With Esophageal Cancer After Combined Modality Therapy

2007 ◽  
Vol 69 (3) ◽  
pp. S584
Author(s):  
R.C. Miller ◽  
P.J. Atherton ◽  
B. Kabat ◽  
M. Fredericksen ◽  
C. Deschamps ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Esophageal Cancer ◽  
Combined Modality Therapy ◽  
Combined Modality

Combined Modality Therapy of Localized Gastric and Esophageal Cancers

2006 ◽  
Vol 4 (4) ◽  
pp. 375-382 ◽  
Author(s):  
Prajnan Das ◽  
Norio Fukami ◽  
Jaffer A. Ajani
Keyword(s):  
Esophageal Cancer ◽  
Combined Modality Therapy ◽  
White Men ◽  
Phase Iii ◽  
Poor Overall Survival ◽  
Esophageal Cancers ◽  
Distant Failure ◽  
Combined Modality ◽  
Staging Surgery

Gastric and esophageal cancers continue to be a significant health problem. The incidence of proximal gastric and distal esophageal cancers has been increasing, especially in white men. Gastric and esophageal cancers have high rates of locoregional and distant failure, resulting in poor overall survival. Therefore, patients with gastric and esophageal cancer may benefit from combined modality therapy. Adjuvant chemoradiation has been shown to improve survival in gastric and gastroesophageal cancers in a phase III trial. In esophageal cancer, most randomized trials have not shown a survival benefit for preoperative chemotherapy or chemoradiation, although these approaches are widely used. This article reviews the role of staging, surgery, and adjuvant and preoperative therapies in the management of localized gastric and esophageal cancers.

Patterns of failure following combined modality therapy for esophageal cancer, 1984–1990

1992 ◽  
Vol 24 (4) ◽  
pp. 633-642 ◽  
Author(s):  
Brian Kavanagh ◽  
Mitchell Anscher ◽  
Kenneth Leopold ◽  
Margaret Deutsch ◽  
Elizabeth Gaydica ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Combined Modality Therapy ◽  
Patterns Of Failure ◽  
Combined Modality

Combined modality therapy for esophageal cancer

1999 ◽  
Vol 1 (2) ◽  
pp. 149-154 ◽  
Author(s):  
Ziv Gamliel ◽  
Mark J. Krasna
Keyword(s):  
Esophageal Cancer ◽  
Combined Modality Therapy ◽  
Combined Modality

INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy

2002 ◽  
Vol 20 (5) ◽  
pp. 1167-1174 ◽  
Author(s):  
Bruce D. Minsky ◽  
Thomas F. Pajak ◽  
Robert J. Ginsberg ◽  
Thomas M. Pisansky ◽  
James Martenson ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Radiation Therapy ◽  
Radiation Dose ◽  
Standard Dose ◽  
Combined Modality Therapy ◽  
High Dose ◽  
Regional Control ◽  
Combined Modality ◽  
Local Regional Control ◽  
Dose Radiation

PURPOSE: To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer. PATIENTS AND METHODS: A total of 236 patients with clinical stage T1 to T4, N0/1, M0 squamous cell carcinoma or adenocarcinoma selected for a nonsurgical approach, after stratification by weight loss, primary tumor size, and histology, were randomized to receive combined-modality therapy consisting of four monthly cycles of fluorouracil (5-FU) (1,000 mg/m2/24 hours for 4 days) and cisplatin (75 mg/m2 bolus day 1) with concurrent 64.8 Gy versus the same chemotherapy schedule but with concurrent 50.4 Gy. The trial was stopped after an interim analysis. The median follow-up was 16.4 months for all patients and 29.5 months for patients still alive. RESULTS: For the 218 eligible patients, there was no significant difference in median survival (13.0 v 18.1 months), 2-year survival (31% v 40%), or local/regional failure and local/regional persistence of disease (56% v 52%) between the high-dose and standard-dose arms. Although 11 treatment-related deaths occurred in the high-dose arm compared with two in the standard-dose arm, seven of the 11 deaths occurred in patients who had received 50.4 Gy or less. CONCLUSION: The higher radiation dose did not increase survival or local/regional control. Although there was a higher treatment-related mortality rate in the patients assigned to the high-dose radiation arm, it did not seem to be related to the higher radiation dose. The standard radiation dose for patients treated with concurrent 5-FU and cisplatin chemotherapy is 50.4 Gy.

Sign in / Sign up

Export Citation Format

Share Document